Valuation: AbbVie Inc.

Market Cap 461B 403B 371B 345B 655B 43,918B 665B 4,449B 1,729B 21,588B 1,731B 1,694B 74,391B P/E 2026 *
32.2x
P/E 2027 * 24.5x
Enterprise Value 517B 452B 415B 387B 734B 49,232B 746B 4,987B 1,939B 24,200B 1,941B 1,899B 83,392B EV / Sales 2026 *
7.69x
EV / Sales 2027 * 6.98x
Free-Float
95.71%
Yield 2026 *
2.65%
Yield 2027 * 2.77%
1 day+3.99%
1 week+7.37%
Current month+3.75%
1 month+21.20%
3 months+25.01%
6 months+13.85%
Current year+14.26%
1 week 247.56
Extreme 247.56
261.64
1 month 215.37
Extreme 215.37
261.64
Current year 190.75
Extreme 190.75
261.64
1 year 184.63
Extreme 184.63
261.64
3 years 132.7
Extreme 132.7
261.64
5 years 105.56
Extreme 105.56
261.64
10 years 55.06
Extreme 55.0623
261.64
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 68 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
05-07Free

Director

1,118 0.0001%
05-07Free

Director

1,118 0.0001%
05-07Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%+7.37%+36.87%+93.77% 461B
+3.45%+7.65%+55.77%+158.84% 1,082B
-1.16%+7.42%+69.09%+58.92% 633B
-0.35%+1.85%+31.30%+24.86% 339B
-0.56%+0.96%+41.67%+39.35% 301B
-0.08%+1.30%+32.15%+44.48% 292B
-1.54%+2.81%-25.35%-39.61% 225B
+3.55%+6.05%+26.04%+68.52% 202B
+0.40%+6.00%+17.72%+70.33% 163B
+1.83%+2.75%-3.95%-33.70% 139B
Average +1.16%+4.36%+28.13%+48.58% 383.83B
Weighted average by Cap. +1.07%+5.32%+40.54%+77.51%

Financials

2026 *2027 *
Net sales 67.24B 58.78B 54.02B 50.35B 95.5B 6,402B 96.95B 648B 252B 3,147B 252B 247B 10,844B 72.73B 63.58B 58.43B 54.47B 103B 6,925B 105B 701B 273B 3,404B 273B 267B 11,730B
Net income 14.56B 12.73B 11.7B 10.9B 20.68B 1,386B 21B 140B 54.6B 682B 54.66B 53.48B 2,348B 19.02B 16.63B 15.28B 14.25B 27.02B 1,811B 27.43B 183B 71.33B 890B 71.41B 69.87B 3,068B
Net Debt 55.81B 48.79B 44.84B 41.79B 79.27B 5,314B 80.47B 538B 209B 2,612B 209B 205B 9,001B 46.34B 40.51B 37.23B 34.7B 65.81B 4,412B 66.81B 447B 174B 2,169B 174B 170B 7,473B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-07-02 US$261.07 +3.99% 7,114,422
26-07-01 US$251.06 -0.23% 6,987,982
26-06-30 US$251.64 -1.05% 6,999,707
26-06-29 US$254.31 +0.38% 9,760,531
26-06-26 US$253.35 +4.20% 52,635,078
Trader
Investor
Global
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
261.07USD
Average target price
256.14USD
Spread / Average Target
-1.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock